Leick Mark B, Maus Marcela V
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Best Pract Res Clin Haematol. 2018 Jun;31(2):158-165. doi: 10.1016/j.beha.2018.03.004. Epub 2018 Mar 28.
Immunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In this review we provide an overview of the toxicity of some of these revolutionary agents including bispecific T cell engagers, checkpoint inhibitors, chimeric antigen receptor T-cells.
免疫疗法为那些对标准治疗方法难治的癌症患者带来了巨大希望。血液系统恶性肿瘤在利用基于细胞的免疫疗法（如嵌合抗原受体T细胞）的最新进展方面处于领先地位，一些患者已实现持久缓解。然而，这些T细胞衔接疗法伴随着一系列新的毒性反应，需要护理人员、肿瘤学家、护士和医护人员进行处理。在本综述中，我们概述了其中一些革命性药物的毒性，包括双特异性T细胞衔接器、检查点抑制剂、嵌合抗原受体T细胞。
